Ezetimibe added to statin therapy after acute coronary syndromes
RESULTS The median time weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin monotherapy group (P<0.001) The Kaplan Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin ezetimibe group, as compared with 34.7% in the simvastatin monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P 0.016) Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE IT ClinicalTrials.gov number, NCT00202878. abstr act